Abstract
Background for the introduction of the SPC legislation in Europe. Effective patent life decreased to less than 10 years. This was considered insufficient to cover the investment into research. Supplementary Protection Certificates (SPCs) to allow longer period of effective protection. Extensive case law - still unclarities in interpretation of the SPC regulation. Technological development in pharmaceutical industry - biotechnological innovation and secondary/second medical use innovation - further challenges to interpretation of the SPC regulation. Aim of the book. Structure of the book. Prior studies on the SPC system.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
